Literature DB >> 24722797

High burden of extended-spectrum β-lactamase-positive Escherichia coli in geriatric patients.

Pak-Leung Ho1, Pui-Hing Chau2, Mei-Kum Yan1, Kin-Hung Chow1, Jonathan H K Chen1, Sally C Y Wong1, Vincent C C Cheng1.   

Abstract

Few studies have described how an expanding elderly population influences the burden of antimicrobial resistance in micro-organisms. This study aimed to investigate trends in age-stratified extended-spectrum β-lactamase (ESBL)-positive Escherichia coli metrics in relation to an ageing population. The antimicrobial resistance database of E. coli from a healthcare region in Hong Kong from 2003 to 2012 was retrospectively reviewed. Future trends in age-stratified ESBL metrics were predicted up to 2022. Susceptibility results of clinical E. coli isolates from patients aged 0-74 years (n = 17 853) and aged ≥75 years (n = 17 047) were analysed. For the period 2003-2012, 23.7 % of the hospital admissions were of patients aged ≥75 years. However, approximately half of the annual ESBL-positive E. coli isolates were recovered from patients aged ≥75 years, being 55.0 % (233/424) in 2003 and 56.0 % (639/1142) in 2012. During this period of time, the annual prevalence and cumulative incidence of ESBL-positive E. coli in patients aged ≥75 years were significantly higher than in patients aged 0-74 years. From 2012-2022, it is predicted that ESBL-positive E. coli prevalence among patients aged 0-74 years and ≥75 years would increase from 25.4 % to 50.2 % and from 30.8 % to 70.0 %, respectively. In 2022, the predicted ESBL-positive E. coli cumulative incidence would be 63.7 per 10 000 admissions and 178.7 per 10 000 admissions among patients aged 0-74 years and ≥75 years, respectively. In conclusion, a rapidly expanding elderly population would substantially add to the burden of ESBL.
© 2014 The Authors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722797     DOI: 10.1099/jmm.0.068270-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  1 in total

1.  Containment of Clostridium difficile infection without reduction in antimicrobial use in Hong Kong.

Authors:  V C C Cheng; P H Chau; S Y C So; J H K Chen; R W S Poon; S C Y Wong; I F N Hung; W M Lee; J W M Tai; P L Ho; W C Yam; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-03-24       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.